Quanterix Corporation · NASDAQ:QTRX
Quanterix — Q2 2025 Earnings Presentation
12 slides from Quanterix's earnings presentation, Aug 7, 2025
Slide 1: Second Quarter 2025 Earnings
„ Second Quarter 2025 Earnings August 7, 2025
Slide 2: Legal Information
Legal Information CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements included in this presentation that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provid
Slide 3: Q2-25: Updates from Last Quarter
Q2-25: Updates from Last Quarter Completed transformative Akoya acquisition Enabling new protein biomarker measurements across tissue and blood continuum Strategic investments to position Quanterix for long-term growth Investments in new assays, Simoa One platform, Alzheimer's Diagnostics Built a $1
Slide 4: Roadmap to Cash Flow Breakeven in 2026
Roadmap to Cash Flow Breakeven in 2026 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Pre-close cost Implement one • Implement one • Complete all Major actions in commercial team Manufacturing Systems and commercial Eliminate duplicate team Financial Milestones G&A and operations • Combine Lab integration •
Slide 5: Building the Global Infrastructure for Alzheimer's Disease Testing
Building the Global Infrastructure for Alzheimer's Disease LucentAD multi- p-Tau217, Aβ42, Aβ40, NfL, GFAP Testing marker test 90% Sensitivity, Specificity and Accuracy with the lowest intermediate zone (~11%) Single-Site IVD in Anticipated submission by end of progress 2025 Crosswalk to several exi
Slide 6: Preliminary Q2 2025 Results vs PYQ2
Preliminary Q2 2025 Results vs PYQ2 (in millions) Q2 GAAP Q2 Non-GAAP INSTRUMENTS CONSUMABLES ACCELERATOR OTHER 2024 2025 2024 2025 Var % Revenue Mix 8% 61% 16% 15% Revenue 34.4 24.5 34.4 24.5 -29% Gross Margin $ 22.2 11.3 20.2 10.2 -49% Gross Margin % 64.7% 46.2% 58.6% 41.8% -1,682 bps Revenue Q2 2
Slide 7: Simoa Scientific Validation Driving Adoption
Simoa Scientific Validation Driving Adoption Neurology Immunology & Oncology Infectious Diseases Others PUBLICATIONS BIOMARKERS INSTRUMENTS Cumulative Cumulative Placements # of units placed In millions USD Cumulative 38.0 275 Number of Drug 256 3,612 576 1,062 Trial Projects 559 568 1,035 538 972 3
Slide 8: 2025 Guidance
2025 Guidance Full Year Revenue: $130 to $135 million $30 million contribution from Spatial. Gross Margin GAAP Gross Margin between 49% to 53% and Adjusted Gross Margin (Non-GAAP) between 45% to 49%. $34 to $38 million of adjusted cash usage $136 million payment for Akoya and Emission acquisitions a
Slide 9: Robust Balance Sheet
Robust Balance Sheet Cash1 ~$163M cash1 at close (July ‘25) 2026 >$100M Cash flow positive in 2026 >$100 million cash1 on hand by the 2025 ~$120M time we turn cash flow positive 1. Includes Cash, Cash Equivalents, Marketable Securities, and Restricted Cash balances from the Consolidated Balance Shee
Slide 10: Adjusted EBITDA (non-GAAP)
Adjusted EBITDA (non-GAAP) 10
Slide 11: Adjusted Cash Usage (non-GAAP)
Adjusted Cash Usage (non-GAAP) 11
Slide 12: Additional Non-GAAP Financial Measures
Additional Non-GAAP Financial Measures 12